Clinical Scorecard: Exploring a New Circuit in the Primary Motor Cortex as a Potential Focus for Neuromodulation Therapy
At a Glance
Category
Detail
Condition
Motor function impairment due to neurological diseases such as stroke and Parkinson’s disease
Key Mechanisms
Identification of inter-effector regions within the primary motor cortex (M1) linked to the somato-cognitive action network, involving white matter connections (plis de passage) bridging motor and sensory cortices and connected to subcortical structures
Target Population
Patients with motor impairments from brain lesions or neurodegenerative diseases
Care Setting
Neurological and neurorehabilitation clinical settings utilizing neuromodulation therapies
Key Highlights
Discovery of three inter-effector regions within M1 that interrupt the classical homunculus and connect to cognitive and motor planning areas.
Plis de passage white matter structures anatomically link these inter-effector regions to the somato-cognitive action network.
Neuromodulation therapies targeting M1 may need to consider differential effects on effector-specific versus inter-effector areas for improved motor recovery.
Guideline-Based Recommendations
Diagnosis
Utilize functional neuroimaging and intraoperative electrical recordings to identify inter-effector regions within M1.
Consider resting-state fMRI connectivity analyses focusing on plis de passage coordinates to map the somato-cognitive action network.
Management
Apply non-invasive neuromodulation techniques (e.g., TMS, tDCS) targeting M1 with awareness of inter-effector and effector-specific regions.
Incorporate knowledge of somato-cognitive action network connectivity to optimize brain stimulation protocols for motor recovery.
Monitoring & Follow-up
Monitor motor evoked potentials (MEPs) elicited by stimulation of inter-effector regions to assess diffuse motor responses.
Track changes in functional connectivity within M1 and related subcortical structures during neuromodulation therapy.
Risks
Recognize interindividual variability in response to neuromodulation therapy post-stroke.
Acknowledge the current unknowns regarding how stimulation of inter-effector areas influences motor system reorganization.
Patient & Prescribing Data
Patients with motor impairments due to stroke or Parkinson’s disease undergoing neuromodulation therapy
Neuromodulation targeting M1 shows moderate efficacy with variability; understanding inter-effector regions may enhance therapeutic outcomes.
Clinical Best Practices
Integrate anatomical and functional mapping of M1 to distinguish effector-specific and inter-effector regions before neuromodulation.
Tailor brain stimulation protocols to engage the somato-cognitive action network for improved sensorimotor integration and motor planning.
Consider subcortical connectivity, especially with basal ganglia and thalamus, when designing neuromodulation strategies.
Use multimodal assessment (histology, neuroimaging, intraoperative recordings) to guide individualized therapy.